Department of Pediatrics, Division of Neuropediatrics and Inherited Metabolic Disorders, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.
Eur J Paediatr Neurol. 2009 Nov;13(6):546-9. doi: 10.1016/j.ejpn.2008.09.006. Epub 2008 Nov 14.
Levetiracetam (LEV) is approved as second line treatment for partial onset seizures in adults and children older than four years of age. Recently, an intravenous formulation was developed as an alternative to standard oral medication. We report the successful treatment of two children suffering from myoclonic status epilepticus with intravenous LEV. Intravenous application of LEV was safe and not associated with significant side effects. In conclusion, intravenous application of LEV appears to be a further option in treatment of children with myoclonic status epilepticus.
左乙拉西坦（LEV）被批准作为成人和 4 岁以上儿童部分发作性癫痫的二线治疗药物。最近，开发了一种静脉制剂作为标准口服药物的替代药物。我们报告了两例患有肌阵挛性癫痫持续状态的儿童使用静脉 LEV 成功治疗的案例。静脉应用 LEV 是安全的，没有明显的副作用。总之，静脉应用 LEV 似乎是治疗肌阵挛性癫痫持续状态儿童的另一种选择。
Zotero 插件